Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548295 | 0.78 | SLC6A4 (0.52) | CHRM2CHRM3OPRM1MBTPS1SLC6A4 | |
| SCHEMBL16826117 | 0.73 | MBTPS1 (0.43) | CHRM3OPRM1MBTPS1SLC6A4SLC6A2 | |
| SCHEMBL548188 | 0.71 | DCUN1D1 (0.51) | SLC6A4SLC6A2 | |
| SCHEMBL11311278 | 0.70 | CACNA2D1 (0.50) | CHRM2CHRM3CACNA2D1OPRM1OPRD1 | |
| SCHEMBL16825796 | 0.69 | CHIA (0.53) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14144500 | 0.67 | SLC6A4 (0.53) | OPRM1MBTPS1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8291857 | 0.66 | CTSD (0.50) | MBTPS1SLC6A4KCNH2 | |
| SCHEMBL28311575 | 0.66 | KMT2A (0.63) | CHRM2CHRM3L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6600053 | 0.65 | NOS1 (0.56) | CHRM2CHRM3KCNH2 | |
| SCHEMBL6600057 | 0.65 | NOS1 (0.56) | CHRM2CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110574-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110574-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110574-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | IPSEN S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | IPSEN S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | IPSEN S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| US-7858789-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858789-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858789-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20090149652-A1 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES | 2009-06-11 | — | — | US | disclosed |
| US-20090149652-A1 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES | 2009-06-11 | — | — | US | disclosed |
| US-20090149652-A1 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES | 2009-06-11 | — | — | US | disclosed |
| EP-1286966-B1 | 4-AMINOPIPERIDINE DERIVATIVES AND THEIR USE AS MEDICINE | SOD CONSEILS RECH APPLIC (FR) | 2008-07-16 | — | — | EP | disclosed |
| US-7393861-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-07-01 | — | — | US | disclosed |
| US-7393861-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-07-01 | — | — | US | disclosed |
| US-7115634-B2 | 4-aminopiperidine and their use as a medicine | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20040006089-A1 | 4-Aminopiperidine and their use as a medicine | IPSEN PHARMA S.A.S. (FR) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149652-A1 | Derivatives of 4-aminopiperidine and their use as a medicament | SSTR4, SSTR3, SSTR1 | CHRM2 57/4885CHRM3 142/4885CACNA2D1 1973/4885 |
| US-20040006089-A1 | 4-Aminopiperidine and their use as a medicine | SSTR1, SSTR2, SSTR4 | CHRM2 89/4885CHRM3 211/4885CACNA2D1 2266/4885 |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | SSTR4, SSTR3, SSTR1 | CHRM2 57/4885CHRM3 142/4885CACNA2D1 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.